Jessica Sorrentino

Jess brings a strong scientific background in biotechnology preclinical and clinical research and development in oncology.

Prior to joining Ribometrix, Jess was the Vice Preclinical of Translational Medicine at Istari Oncology supporting the development of an oncolytic virus for the treatment of multiple tumor indications including GBM, melanoma, and NMIBC. Additionally, Dr. Sorrentino was the Director of Translational Medicine and Biomarkers at G1Therapeutics where she led the translational program the three clinical-stage small molecule inhibitors including NDA approval of Trilaciclib in SCLC. Dr. Sorrentino has also served as an independent consultant working for other life science companies.

Dr. Sorrentino earned a PhD in toxicology from the University of North Carolina at Chapel Hill studying the role of chronic environmental toxicant exposure leading to both an advanced aging and tumorigenic phenotype Jess was also a Howard Hughes Scholar in the UNC Graduate Translational Medicine Training Program. Lastly, she earned her B.S. in Molecular Genetics from the University of Rochester in Rochester, NY.